Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Neoadjuvant chemotherapy is increasingly utilized in patients with borderline or locally advanced pancreatic cancer (LAPC). However, the pathologic evaluation of tumor regression is not routinely performed or well established. We aimed to evaluate the prognostic value of three tumor regression grading systems frequently used in LAPC and to determine the correlation between pathologic and clinical response. Methods: We included a total of 38 patients with LAPC who were treated with neoadjuvant chemotherapy and subsequent resection. Pathologic tumor regression was graded based on the College of American Pathologists (CAP), Evans, and MD Anderson grading systems. Results: One out of 38 patients (2.6%) achieved a pathologic complete response. Unlike other grading systems (Evans, p=0.063; MD Anderson, p=0.110), the CAP grading system was a significant prognostic factor for overall survival (p=0.043). Pathologic N stage (p=0.023), margin status (p=0.044), and radiologic response (p=0.016) correlated with overall survival. In the multivariate analysis, CAP 3 was an independent predictor of shorter overall survival (p=0.026). The CAP grading system correlated with the radiologic response (p=0.007) but not the carbohydrate antigen 19-9 level (p=0.333). Conclusions: The four-tier CAP pathologic tumor regression grading system predicted the clinical outcome in LAPC patients who underwent resection after neoadjuvant chemotherapy. Therefore, a more comprehensive pathologic evaluation is warranted in these patients.
Abstract
Background/Aims: Neoadjuvant chemotherapy is increasingly utilized in patients with borderline or locally advanced pancreatic cancer (LAPC). However, the pathologic evaluation of tumor regression is not routinely performed or well established. We aimed to evaluate the prognostic value of three tumor regression grading systems frequently used in LAPC and to determine the correlation between pathologic and clinical response. Methods: We included a total of 38 patients with LAPC who were treated with neoadjuvant chemotherapy and subsequent resection. Pathologic tumor regression was graded based on the College of American Pathologists (CAP), Evans, and MD Anderson grading systems. Results: One out of 38 patients (2.6%) achieved a pathologic complete response. Unlike other grading systems (Evans, p=0.063; MD Anderson, p=0.110), the CAP grading system was a significant prognostic factor for overall survival (p=0.043). Pathologic N stage (p=0.023), margin status (p=0.044), and radiologic response (p=0.016) correlated with overall survival. In the multivariate analysis, CAP 3 was an independent predictor of shorter overall survival (p=0.026). The CAP grading system correlated with the radiologic response (p=0.007) but not the carbohydrate antigen 19-9 level (p=0.333). Conclusions: The four-tier CAP pathologic tumor regression grading system predicted the clinical outcome in LAPC patients who underwent resection after neoadjuvant chemotherapy. Therefore, a more comprehensive pathologic evaluation is warranted in these patients.
참고문헌 (28)
- Saad AM, "Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study", BMC Cancer, 18, pp.688~ (2018)
- Alexakis N, "Current standards of surgery for pancreatic cancer", Br J Surg, 91, pp.1410~1427 (2004)
- Balaban EP, "Locally advanced unresectable pancreatic cancer : American Society of Clinical Oncology clinical practice guideline summary", J Oncol Pract, 13, pp.265~269 (2017)
- Heinrich S, "Neoadjuvant therapy of pancreatic cancer : definitions and benefits", Int J Mol Sci, 18, pp.1622~ (2017)
- Russo S, "Neoadjuvant therapy for pancreatic cancer : an ongoing debate", Therap Adv Gastroenterol, 9, pp.429~436 (2016)
- Evans DB, "Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head", J Clin Oncol, 26, pp.3496~3502 (2008)
- Dhir M, "Neoadjuvant treatment of pancreatic adenocarcinoma : a systematic review and meta-analysis of 5520 patients", World J Surg Oncol, 15, pp.183~ (2017)
- Kim SS, "Comparison of tumor regression grading of residual pancreatic ductal adenocarcinoma following neoadjuvant chemotherapy without radiation : would fewer tier-stratification be favorable toward standardization?", Am J Surg Pathol, 43, pp.334~340 (2019)
- Lee SM, "Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival", Am J Surg Pathol, 40, pp.1653~1660 (2016)
- Zhao Q, "Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis", Ann Diagn Pathol, 16, pp.29~37 (2012)
- Chatterjee D, "Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma : a predictor for patient outcome", Cancer, 118, pp.3182~3190 (2012)
- Truty MJ, "Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline", locally advanced pancreatic cancer, 2021, pp.273, 341~349
- Shi C, "Protocol for the examination of specimens from patients with tumors of the endocrine pancreas. Version PancreasExocrine 4.0.0.1", College of American Pathologists, ~ (2017)
- Evans DB, "Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas", Arch Surg, 127, pp.1335~1339 (1992)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Lambert A, "An update on treatment options for pancreatic adenocarcinoma", Ther Adv Med Oncol, 11, pp.1758835919875568~ (2019)
- Pai RK, "Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy", Mod Pathol, 31, pp.4~23 (2018)
- Cacciato Insilla A, "Tumor regression grading assessment in locally advanced pancreatic cancer after neoadjuvant FOLFIRINOX : interobserver agreement and prognostic implications", Front Oncol, 10, pp.64~ (2020)
- Verbeke C, "Pathology reporting of pancreatic cancer following neoadjuvant therapy : challenges and uncertainties", Cancer Treat Rev, 41, pp.17~26 (2015)
- 김경수, "Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis", Cancer Research and Treatment, 49(3), pp.824~833 (2017), 대한암학회
- Washington MK, "Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum", Arch Pathol Lab Med, 133, pp.1539~1551 (2009)
- Gosens MJ, "Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma", Clin Cancer Res, 13, pp.6617~6623 (2007)
- Xia BT, "Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?", J Surg Oncol, 115, pp.376~383 (2017)
- Cassinotto C, "Locally advanced pancreatic adenocarcinoma : reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy", Radiology, 273, pp.108~116 (2014)
- Sherman WH, "Predictors of response and survival in locally advanced adenocarcinoma of the pancreas following neoadjuvant GTX with or without radiation therapy", Oncologist, 23, pp.4~ (2018)[DOI]
- Poruk KE, "The clinical utility of CA 19-9 in pancreatic adenocarcinoma : diagnostic and prognostic updates", Curr Mol Med, 13, pp.340~351 (2013)
- Reni M, "Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma", Ann Oncol, 28, pp.2786~2792 (2017)
- Kalimuthu SN, "Regression grading in neoadjuvant treated pancreatic cancer : an interobserver study", J Clin Pathol, 70, pp.237~243 (2017)